Ontology highlight
ABSTRACT:
SUBMITTER: Wang J
PROVIDER: S-EPMC5960314 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Wang Jingxin J Schultz Peter G PG Johnson Kristen A KA
Proceedings of the National Academy of Sciences of the United States of America 20180430 20
RG-7916 is a first-in-class drug candidate for the treatment of spinal muscular atrophy (SMA) that functions by modulating pre-mRNA splicing of the <i>SMN2</i> gene, resulting in a 2.5-fold increase in survival of motor neuron (SMN) protein level, a key protein lacking in SMA patients. RG-7916 is currently in three interventional phase 2 clinical trials for various types of SMA. In this report, we show that SMN-C2 and -C3, close analogs of RG-7916, act as selective RNA-binding ligands that modul ...[more]